¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© o(k{Ed  
ysj5/wtO0  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Vw|P;LLl`  
  1¡¢Co-stimulators (or co-stimulating molecules) `Gj(>z*  
  2¡¢NK-kB g<N;31:c\  
  3¡¢Immunoglobulin superfamily .* )e24`  
  4¡¢antigen-presenting cell (APC) )bWopc  
  5¡¢death domain 5a-x$Qb9  
  6¡¢CCR and CXCR I>GBnx L  
  7¡¢Lectin (or mitogen) gYCr,-_i  
  8¡¢Clusters of differentiation, CD) 9Pb6 Z}  
  9¡¢B7 family _ 6SAU8M,  
  10¡¢Cytotoxic T lymphocyte, CTL) Xhq7)/jp  
  11¡¢IL-15 and IL-15 receptor (IL-15R) Pa6pq;4St  
  12¡¢MHC restriction MkL)  
  13¡¢Affinity-chromatography R RE8|%p;B  
  14¡¢Cyctosprin A, CsA CLTkyS)C  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) V)5K/ U{  
| UlG@Mn  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© !> =ybRe  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 *s,[Uy ![  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ?G5,}%  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ lXg5UrW  
$&=xw _  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© *i}X(sfe  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ xorafL  
  ѪҺ²¡Ñ§×¨Òµ£º 4EHrd;|   
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»